THE US Food and Drug
Administration has shut down a
trial of the thyroid drug, Sensipar,
by Amgen, following the death of a
14-year old patient during the
drug’s trial.
Sensipar is currently approved in
the US to treat over-activity of the
parathyroid gland in adults, and the
trial was testing whether the drug
would be suitable for treating the
condition in children.The above article was sent to subscribers in Pharmacy Daily's issue from 27 Feb 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Feb 13
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.